Gabapentin + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Transient Insomnia
Conditions
Transient Insomnia
Trial Timeline
Dec 1, 2004 → May 1, 2005
NCT ID
NCT00666575About Gabapentin + Placebo
Gabapentin + Placebo is a phase 3 stage product being developed by Pfizer for Transient Insomnia. The current trial status is completed. This product is registered under clinical trial identifier NCT00666575. Target conditions include Transient Insomnia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01052896 | Phase 3 | Withdrawn |
| NCT00163046 | Phase 3 | Completed |
| NCT00666575 | Phase 3 | Completed |
Competing Products
10 competing products in Transient Insomnia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2624803 - Capsules + Zolpidem - Tablets + Placebo - Capsules + Placebo - Tablets | Eli Lilly | Phase 1 | 33 |
| Gabapentin + Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin + Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin + Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin + Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin | Pfizer | Phase 3 | 76 |
| Milvexian + Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| Apixaban + Warfarin | Bristol Myers Squibb | Phase 3 | 76 |
| Levosimendan + Placebo | Orion Corporation | Phase 2 | 49 |